PATE2

Summary

PATE2 (prostate and testis expressed 2, HGNC:32249) is a protein-coding gene on chromosome 11q24.2, encoding Prostate and testis expressed protein 2 (Q6UY27).

Located in extracellular space.

Source: NCBI Gene 399967 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 25 total
• MANE Select transcript: NM_212555

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32249
Approved symbol	PATE2
Name	prostate and testis expressed 2
Location	11q24.2
Locus type	gene with protein product
Status	Approved
Aliases	UNQ3112, LVLF3112, PATE-M
Ensembl gene	ENSG00000196844
Ensembl biotype	protein_coding
Entrez	399967

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000358524, ENST00000436890

RefSeq mRNA: 1 — MANE Select: NM_212555 NM_212555

CCDS: CCDS8465

Canonical transcript exons

ENST00000358524 — 4 exons

Exon	Start	End
ENSE00001400817	125776113	125777518
ENSE00001410092	125778722	125778828
ENSE00001431487	125778552	125778575
ENSE00001433601	125777874	125778002

Expression profiles

Bgee: expression breadth broad, 57 present calls, max score 98.86.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3251 / max 251.3825, expressed in 9 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
123005	0.3177	9
123004	0.0074	3

Top tissues by expression

207 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
corpus epididymis	UBERON:0004359	98.86	gold quality
cauda epididymis	UBERON:0004360	93.71	gold quality
seminal vesicle	UBERON:0000998	85.63	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.88	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	72.63	gold quality
sperm	CL:0000019	68.30	silver quality
pancreatic ductal cell	CL:0002079	63.22	silver quality
caput epididymis	UBERON:0004358	62.85	gold quality
tibialis anterior	UBERON:0001385	59.52	silver quality
ileal mucosa	UBERON:0000331	55.19	silver quality
epithelial cell of pancreas	CL:0000083	55.04	gold quality
cardiac muscle of right atrium	UBERON:0003379	54.34	gold quality
left ventricle myocardium	UBERON:0006566	54.23	gold quality
deltoid	UBERON:0001476	54.14	gold quality
kidney epithelium	UBERON:0004819	53.93	gold quality
upper arm skin	UBERON:0004263	53.52	gold quality
myocardium	UBERON:0002349	50.25	gold quality
skin of hip	UBERON:0001554	50.08	silver quality
prefrontal cortex	UBERON:0000451	48.41	gold quality
cerebellar vermis	UBERON:0004720	48.32	gold quality
quadriceps femoris	UBERON:0001377	47.55	gold quality
nasal cavity epithelium	UBERON:0005384	47.03	gold quality
testis	UBERON:0000473	46.11	gold quality
left testis	UBERON:0004533	45.48	gold quality
vastus lateralis	UBERON:0001379	45.40	gold quality
buccal mucosa cell	CL:0002336	44.22	gold quality
frontal cortex	UBERON:0001870	44.08	gold quality
amniotic fluid	UBERON:0000173	43.94	gold quality
layer of synovial tissue	UBERON:0007616	43.55	gold quality
thymus	UBERON:0002370	43.51	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.10

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

70 targeting PATE2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-2681-5P	99.75	67.64	1655
HSA-MIR-518A-5P	99.70	69.01	2209
HSA-MIR-527	99.70	69.01	2209
HSA-MIR-7157-5P	99.66	69.33	1829
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-7112-5P	99.59	65.76	104
HSA-MIR-3136-3P	99.57	66.59	781
HSA-MIR-7155-3P	99.57	66.48	794
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-657	99.48	66.02	848
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-3922-3P	99.25	64.96	1136
HSA-MIR-3176	99.25	64.35	954

Literature-anchored findings (GeneRIF, showing 2)

• analysis of PATE, expressed primarily in prostate and less in testis, and additional PATE-like genes PATE-M, PATE-DJ, and PATE-B (PMID:18387948)
• PATE proteins are involved in sperm-oolemma fusion and penetration but not sperm-zona binding. (PMID:22402205)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Pate2	ENSMUSG00000074452
rattus_norvegicus	Pate2	ENSRNOG00000033981

Paralogs (4): ACRV1 (ENSG00000134940), PATE1 (ENSG00000171053), PATE3 (ENSG00000236027), PATE4 (ENSG00000237353)

Protein

Protein identifiers

Prostate and testis expressed protein 2 — Q6UY27 (reviewed: Q6UY27)

Alternative names: PATE-like protein M

All UniProt accessions (1): Q6UY27

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Secreted.

Tissue specificity. Isoform 1 and isoform 2 are expressed in prostate and testis. Isoform 2 is expressed in male and female brain at equivalent levels, in particular in cerebellum, cerebral cortex, corpus callosum, occipital, parrietal and temporal lobes, and pons, but not in amygdala, cerebral peduncle, hippocampus and thalamus.

Similarity. Belongs to the PATE family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6UY27-1	1	yes
Q6UY27-2	2

RefSeq proteins (1): NP_997720* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR016054	LY6_UPA_recep-like	Domain
IPR029691	PATE2	Family
IPR059168	PATE2-like_ECD_3FTx	Domain

Pfam: PF00021

UniProt features (8 total): disulfide bond 4, signal peptide 1, chain 1, domain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6UY27-F1	86.09	0.71

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (4): 31–57, 34–42, 49–80, 84–101

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 21 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_UP, chr11q24, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, MIR6867_5P, MIR619_5P, MIR12128, MIR6506_5P, MIR4330, MIR3922_3P, MIR5591_3P, JINESH_BLEBBISHIELD_VS_LIVE_CONTROL_UP, KANNAN_BLOOD_2012_2013_TIV_AGE_65PLS_REVACCINATED_IN_6_9_MO_VS_REVACCINATED_IN_12_13_MOS_DN, GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_24H_ACT_CD4_TCELL_DN, GSE18791_UNSTIM_VS_NEWCATSLE_VIRUS_DC_18H_DN, GSE2770_UNTREATED_VS_TGFB_AND_IL4_TREATED_ACT_CD4_TCELL_48H_UP

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (2): obsolete extracellular space (GO:0005615), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	1

Protein interactions and networks

STRING

290 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PATE2	PATE3	B3GLJ2	848
PATE2	PATE4	P0C8F1	816
PATE2	PATE1	Q8WXA2	758
PATE2	LY6L	H3BQJ8	697
PATE2	PINLYP	A6NC86	644
PATE2	LYPD5	Q6UWN5	605
PATE2	GLB1L3	Q8NCI6	590
PATE2	LYPD4	Q6UWN0	585
PATE2	LY6G5B	Q8NDX9	582
PATE2	SPACA4	Q8TDM5	575
PATE2	LY6H	O94772	570
PATE2	LY6G6F	Q5SQ64	570
PATE2	GLB1L	Q6UWU2	560
PATE2	GLB1L2	Q8IW92	560
PATE2	LY6G5C	Q5SRR4	548

IntAct

2 interactions, top by confidence:

A	B	Type	Score
PATE2	ANXA3	psi-mi:“MI:0914”(association)	0.350

BioGRID (4): S100A4 (Affinity Capture-MS), ANXA3 (Affinity Capture-MS), CACNA2D2 (Affinity Capture-MS), ALDH1A3 (Affinity Capture-MS)

ESM2 similar proteins: A0A346CIB0, B3GLJ2, B3GLJ3, C1IC49, O42255, O42256, O73857, O93471, O93472, P01442, P0C8F1, P15818, P43445, P58370, P60301, P60302, P60303, P60304, P60310, P60814, P79810, P81827, P81828, P82935, P83121, Q00996, Q09098, Q2VBN2, Q2VBP1, Q2VBP3, Q3UN54, Q3UW31, Q53B47, Q6UY27, Q70WS8, Q7ZT13, Q802B3, Q8AY52, Q8AY53, Q98958

Diamond homologs: Q3UW31, Q6UY27

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

25 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	23
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

304 predictions. Top by Δscore:

Variant	Effect	Δscore
11:125778716:ACTT:A	donor_loss	1.0000
11:125778717:CTT:C	donor_loss	1.0000
11:125778718:TTAC:T	donor_loss	1.0000
11:125778719:TACCC:T	donor_loss	1.0000
11:125778720:A:AC	donor_gain	1.0000
11:125778720:A:AG	donor_loss	1.0000
11:125778720:AC:A	donor_gain	1.0000
11:125778720:ACC:A	donor_gain	1.0000
11:125778721:C:CC	donor_gain	1.0000
11:125778721:C:CG	donor_loss	1.0000
11:125778721:CC:C	donor_gain	1.0000
11:125778721:CCC:C	donor_gain	1.0000
11:125778715:GACTT:G	donor_loss	0.9900
11:125778720:ACCC:A	donor_gain	0.9900
11:125778721:CCCC:C	donor_gain	0.9900
11:125778721:CCCCA:C	donor_gain	0.9900
11:125778773:T:TA	donor_gain	0.9800
11:125778460:ACAGG:A	donor_gain	0.9600
11:125778461:CAGGC:C	donor_gain	0.9600
11:125777519:C:CC	acceptor_gain	0.9300
11:125778457:A:AC	donor_gain	0.9100
11:125778513:G:A	donor_gain	0.9100
11:125777514:CTGCC:C	acceptor_gain	0.8800
11:125778514:CCTGT:C	donor_gain	0.8500
11:125778464:G:A	donor_gain	0.8200
11:125777517:CC:C	acceptor_gain	0.7900
11:125777518:CC:C	acceptor_gain	0.7900
11:125777409:G:C	donor_gain	0.7800
11:125777287:CAA:C	acceptor_gain	0.7400
11:125777389:C:CA	donor_gain	0.7400

AlphaMissense

750 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:125777909:C:G	C57S	0.994
11:125777910:A:T	C57S	0.994
11:125777498:A:G	S76P	0.993
11:125777404:C:G	C107S	0.991
11:125777405:A:T	C107S	0.991
11:125777485:C:G	C80S	0.991
11:125777486:A:T	C80S	0.991
11:125777404:C:T	C107Y	0.989
11:125777506:T:C	Y73C	0.989
11:125777909:C:T	C57Y	0.989
11:125777954:C:G	C42S	0.989
11:125777955:A:T	C42S	0.989
11:125777400:G:C	N108K	0.988
11:125777400:G:T	N108K	0.988
11:125777987:C:G	C31S	0.987
11:125777988:A:T	C31S	0.987
11:125777403:G:C	C107W	0.986
11:125777473:C:G	C84S	0.986
11:125777473:C:T	C84Y	0.986
11:125777474:A:T	C84S	0.986
11:125777485:C:T	C80Y	0.986
11:125777489:A:G	S79P	0.986
11:125777491:A:G	L78P	0.986
11:125777907:C:G	A58P	0.986
11:125777908:A:C	C57W	0.986
11:125777953:G:C	C42W	0.986
11:125777955:A:G	C42R	0.986
11:125777978:C:G	C34S	0.986
11:125777979:A:T	C34S	0.986
11:125777405:A:G	C107R	0.985

dbSNP variants (sampled 300 via entrez): RS1001056678 (11:125776269 G>T), RS1001383085 (11:125776030 A>G), RS1001567059 (11:125776044 C>A,T), RS1002187920 (11:125776290 G>A), RS1002870734 (11:125780105 C>G,T), RS1003583616 (11:125779716 C>T), RS1003879667 (11:125778440 T>A), RS1005596407 (11:125780492 A>G), RS1005812804 (11:125780281 T>A), RS1006415512 (11:125778669 A>G), RS1006675128 (11:125780439 G>A), RS1006686440 (11:125780188 C>A), RS1007045696 (11:125779032 T>C), RS1008643748 (11:125775963 A>G), RS1009381930 (11:125777607 C>T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002861_2	Breast cancer (survival)	1.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0000714	survival time

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases methylation	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Silicon Dioxide	decreases expression	1
Asbestos, Crocidolite	decreases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.